<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464045</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0097</org_study_id>
    <nct_id>NCT03464045</nct_id>
  </id_info>
  <brief_title>Empa PASS on Urinary Tract Malignancies</brief_title>
  <official_title>Post-authorisation Safety Study to Assess the Risk of Urinary Tract Malignancies in Relation to Empagliflozin Exposure in Patients With Type 2 Diabetes: a Multi-database European Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the risk of urinary tract malignancies in patients
      initiating empagliflozin (free or fixed dose combination) compared to patients initiating a
      dipeptidyl peptidase-4 (DPP-4) inhibitor and to patients initiating other Sodium glucose
      co-transporter-2 (SGLT-2) inhibitors (i.e. two comparator groups)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 16, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>occurence of urinary tract cancer</measure>
    <time_frame>upto 60 months</time_frame>
    <description>first incidence of urinary cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>occurence of bladder cancer</measure>
    <time_frame>upto 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>occurence of renal cancer</measure>
    <time_frame>upto 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurence of other urinary tract cancers</measure>
    <time_frame>upto 60 months</time_frame>
    <description>non-renal, non- urinary bladder, urinary tract cancers</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5500</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>type 2 diabetes patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin</intervention_name>
    <description>drug</description>
    <arm_group_label>type 2 diabetes patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPP-4 inhibitors</intervention_name>
    <description>drug</description>
    <arm_group_label>type 2 diabetes patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT-2 inhibitors</intervention_name>
    <description>drug</description>
    <arm_group_label>type 2 diabetes patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is an observational, comparative, cohort safety study based on European healthcare
        databases and includes databases from the UK and Sweden.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes

          -  Age over 18 years at index date

          -  At least 1 year of membership in the medication database prior to index date

        Exclusion Criteria:

          -  Patients with any cancer (excluding non-melanoma skin cancer) recorded at any time
             prior to the index date (i.e. during the available look-back time)

          -  Diagnosis of type 1 diabetes or other specific non-type 2 diabetes

          -  Use of any SGLT-2 inhibitor or any DPP-4 inhibitor (including free and fixed-dose
             combinations) recorded at any time prior to index date (i.e. during the available
             look-back time).

          -  Use of fixed-dose combinations of SGLT-2 inhibitors with DPP-4 inhibitors

          -  Diagnosis of end stage renal disease or receipt of renal dialysis recorded at any time
             prior to index date (i.e. during the available look-back time)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasi Korhonen, 358-50-3652990</last_name>
    <role>Principal Investigator</role>
    <affiliation>pasi.korhonen@epidresearch.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The National Register Data</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Swedish prescribed drug register</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Kingdom Clinical Practice Research Datalink (CPRD)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

